



GB00/517

The  
Patent  
Office

PCT/GB 00 / 00 5 17



INVESTOR IN PEOPLE

09/9/3522

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 13 APR 2000

WIPO PCT

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*Am. B. Jones*

Dated 27 March 2000

### BEST AVAILABLE COPY

An Executive Agency of the Department of Trade and Industry

**THIS PAGE BLANK (USPTO)**

1/77  
18 FEB 99 12:26:11 -1 D10007  
P01/7700 0.00 - 9903584.2

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

18 FEB 1999

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

P1082

2. Patent application number

(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)

THE UNIVERSITY OF LEEDS  
RESEARCH SUPPORT UNIT  
LEEDS  
LS2 9JT

Patents ADP number (if you know it)

798322003-

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

MODIFIED CALYCINS

5. Name of your agent (if you have one)

MARKGRAAF PATENTS LIMITED

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

THE CRESCENT  
54 BLOSSOM STREET  
YORK  
YO24 1AP

HARRISON GODDARD FOOTE  
BELMONT HOUSE  
20 WOOD LANE  
LEEDS. LS6 2AE

5/1/77  
28.10.99

Patents ADP number (if you know it)

7295676002 14571001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description

Claim(s)

Abstract

Drawing(s)

17 ✓ *SSM*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

*Mark Graaf Patents Ltd*

Date

17/02/99

MARKGRAAF PATENTS LIMITED

12. Name and daytime telephone number of person to contact in the United Kingdom

DR ROB C DOCHERTY

01904 610586

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500503.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## MODIFIED CALYCINS

The invention herein described relates to the use of calycins, and in particular, the use of lipocalins in the hair care industry, and more particularly to the transport and/or binding of ligands to hair fibres and also the modification of lipocalins to alter the specificity of said lipocalins for said fibres and/or said ligands.

Lipocalins are a diverse family of extracellular proteins found in biological organisms. They display various functions related to the binding and transport of ligands. For example, they are involved in mediating pheromone activity, olfaction, taste, vision, immunomodulation and general functions relating to cellular homeostasis.

Arguably the most extensively studied lipocalin is the retinol binding protein (RBP) which transports retinol around the body. Retinol (or vitamin A) is an extremely important substance which is crucial to the normal functioning of the visual, the reproductive and the immune systems, and in haematopoiesis. Further, metabolites of retinol are active in development and differentiation and against cancer cells.

During embryonic development, a deficiency in vitamin A (retinol) can lead to tetratogenic effects on the development of the nervous system, eyes, face, teeth, ears, limbs, skin, lungs and the urinogenital system. The importance of maintaining the optimal concentration of retinol is also shown by the effects of excess retinol on the developing embryo and on the adult. This too can lead to abnormal development of many organs and to toxic effects leading to disability and death.

and death.

The body stores retinol in the liver cells from which it is mobilised when required. RBP complexes with retinol in the cell and the complex is secreted into the plasma from where it can reach almost all tissues. RBP is not freely diffusible in the plasma but is associated with a further protein, transthyretin (TTR). TTR has several functions including retaining RBP in the plasma. RBP also interacts with a further protein bound at the cell surface of tissues targeted for retinol, the so called RBP receptor. The binding of RBP to this receptor induces the release and uptake by the cell of retinol, which can then be utilised for a large variety of metabolic and regulatory processes. The receptor has now been cloned and encodes a polypeptide of 63kDa ( please see US 5,573, 939 and US 5 573 939). RBP is, therefore, a very versatile protein, being able to interact with retinol and at least two macromolecules in a highly specific manner.

The 3-dimensional structure of RBP was determined in 1984 and revealed a novel structure. As many more lipocalins were identified and characterised, it became apparent that this basic eight- $\beta$ -stranded structure was conserved in all the structural homologues although the overall level of amino acid sequence identity is low. This family of proteins became known as the lipocalins (derived from the Greek word lipos, meaning fat and calyx meaning cup). A closely related family of 10- $\beta$ -stranded intracellular protein has also been found, the two groups together comprising the calycins.

The lipocalins are found throughout biological life and range in molecular weight from approximately 18kDa to 45kDa. However, this represents the

monomeric molecular form; many lipocalins exist in as multimers. For example the bilin-binding protein exists as a homotetramer of a 19.5kDa monomeric subunit. Apolipoprotein D exists as a dimer, but is also associated with other proteins. RBP is found complexed with TTR in up to a 1:1 ratio, while crustacyanin appears to contain 16 subunits in its stable molecular form.

As mentioned previously, the lipocalins are not highly conserved at the amino acid level, but do retain certain structural features that make them recognisable as lipocalins. The core structure is represented by orthogonally arranged  $\beta$ -sheets, the  $\beta$ -strands connected to each other to form a barrel-like structure closed at one end, thereby producing the 'cup shaped' structure. The cavity thus created represents the binding pocket for the ligand transported/bound by the lipocalin. There are some short regions of sequence homology that help to identify a protein as a lipocalin. The two most definitive but not obligatory being the GXW and TDY motifs.

The major function of the lipocalins is the binding and transport of specific ligands (although at least one has enzymic activity) which are usually small hydrophobic molecules. The specificity of binding is determined by the conformation and constituent side-chains of the lipocalin pocket. It is of note that *in vitro* many lipocalins can bind with high affinity to a range of hydrophobic molecules not normally encountered in nature. This may represent an inherent ability of the lipocalins to bind molecules having particular biochemical and structural properties.

The realisation that RBP binds not only retinol and TTR, but also the membrane-associated retinoic acid receptor, indicates that RBP contains

specific domains that enable it to interact with cellular targets with relatively high affinity and specificity. Indeed, we have found that one can alter the specificity of a lipocalin by genetically engineering into same regions involved in receptor recognition so as to target a lipocalin (and a ligand) to a specific tissue or site in the body.

Another example of a lipocalin which has been extensively studied is  $\beta$ -lactoglobulin.  $\beta$ -lactoglobulin is a very abundant protein found in the milk of mammals. The monomer molecular weight of bovine  $\beta$ -lactoglobulin is 18kDa, corresponding to 162 amino acids. A number of investigators have shown that  $\beta$ -lactoglobulin binds retinol and fatty acids *in vitro*. However, the exact role played by  $\beta$ -lactoglobulin *in vivo* is still not understood.

We investigated the potential of  $\beta$ -lactoglobulin to bind fatty acids at a non-native site. The term non-native is defined as a targetting site not naturally encountered by a lipocalin. The hair cuticle is thought to be coated in fatty acids, these fatty acids may function as a hydrophobic barrier to water and they also give hair its natural sheen and texture. Cosmetic hair conditioners function to accentuate these features of hair. However, conditioners currently available only have a transient association with the hair cuticle and therefore the user has to periodically apply conditioner to maintain the sheen and body of the hair. We demonstrate that lipocalins, for example  $\beta$ -lactoglobulin, can be adapted to provide a conditioning property to hair. The majority of hair products contain protein which is claimed to imbue the hair with body and protective elements. However, the ability of these protein additives to bind human hair with high affinity is questionable. In contrast the affinity of  $\beta$ -lactoglobulin for the fatty acids that coat hair cuticles allows a lipocalin based conditioner to be

formulated which binds tightly to hair and imparts a variety of desirable properties. In addition lipocalins that bind hair can impart other beneficial features to hair by altering, for example, the charge on the protein to alter its hydrophobicity thereby conferring body to the hair fibres it binds. Further, lipocalins that bind hair may be post-translationally modified ( eg glycosylation, lipidation) to alter the feel and/or sheen of hair bound by the modified lipocalin. Alternatively, lipocalins can be adapted to carry a variety of agents to hair to provide an indirect conditioning and protective effect.

Additionally or alternatively multimeric complexes of lipocalins can be adapted to carry more than one beneficial agent to hair. For example, and not by way of limitation, multimeric lipocalin complexes can be used to carry both conditioning agents and fragrances to hair. Fragrance molecules are generally volatile. The binding of fragrance molecules to a lipocalin will provide for delayed and/or controlled release. One example of such a lipocalin is the pyrazine- binding protein which binds bell-pepper odourant 3-isobutyl-3-methoxypyrazine. Alternatively lipocalins can be selected from libraries to bind an odourant of choice.

Also, other haircare products can be developed with multi-functional properties. For instance, the fatty acid binding domain of one lipocalin may be complexed with the ligand binding domain of another lipocalin.

In this respect the pigmented lipocalin, crustacyanin, has also been sequenced and modelled by us. The ligand in this instance is a carotenoid, astaxanthin, and there are a number of such lipocalin-carotenoid complexes in nature. The interaction between carotenoid and lipocalin produces a change in the

absorbance characteristics of the astaxanthin, such that the complex now assumes a different colour. It is, therefore, proposed that such coloured complexes may be engineered for use as specific hair colorants.

Also in recent years, hair mite has become a common problem in schools, mainly due to the phasing out over the last 15-20 years of head inspections in schools by nursing staff. Currently, treatment of hair mite infections is by administration of an insecticidal shampoo (pyrethroid based) which is effective at removing the primary infection, but does not provide prophylactic treatment (and has given grounds for safety concern). Therefore, re-infection is common, leading to rounds of treatment using expensive (and questionable) insecticidal shampoos. It would therefore be highly desirable to produce shampoo for prophylactic treatment which has long lasting effects based on the tight binding and the slow release of insecticidal agents preferably of low concentration. Such formulation may also have value as insect repellents.

Moreover animals, both domestic and/or livestock, suffer greatly from various parasitic infections of the outer surface of the body. It would therefore be highly desirable, to produce anti-parasitic complexes that remain bound to fibres of fur, hide, or feathers to prevent and/or cure parasitic infections, preferably by the slow release of toxic agents.

It is therefore an object of the invention to provide a lipocalin or lipocalin complex for use in the treatment of hair.

It is a further object of the invention to provide a lipocalin or lipocalin complex for use in the delivery of agents which prevent and/or cure various hair and/or

scalp conditions.

In its broadest aspect the invention concerns the modification of either, or both, the ligand binding domain and/or targetting domain of a lipocalin in order to provide for the selective delivery of at least one ligand to a hair fibre.

According to a first aspect of the invention there is provided a lipocalin (or agent encoding same) comprising; a binding domain for binding at least one selected hair treatment product; and a targeting domain that binds to at least a part of a hair fibre for targeting said lipocalin to said hair fibre.

Reference herein to the term targetting is intended to include, without limitation, the preferential or selective location or binding of said lipocalin to said fibre.

In a preferred embodiment of the invention said lipocalin further comprises a subunit interaction domain that allows for the multimeric assembly of said lipocalins. In this respect said subunit interaction domain may be a naturally occurring part of said lipocalin, or alternatively, it may be inserted with same using conventional synthetic or recombinant techniques.

It will be apparent to the skilled artisan that said binding domain and/or said targeting domain may be endogenous to said lipocalin, however, in the instance where said lipocalin would not naturally bind a hair treatment product or a hair fibre the corresponding binding and/or targeting domain is adapted accordingly. This adaption may comprise either the alteration of the existing binding and/or targeting domain or the substitution of same for a domain that has the required functionality.

It will be apparent from the description that in simple terms a lipocalin can be functionally divided into a “binding domain” and a “targetting domain”. The “binding domain” functions to interact with ligands and the “targetting domain” functions to provide specificity in transporting the bound ligand to a defined site. In some instances the binding domain may also be part of the targetting mechanism. Further, the subunit interaction domain functions to allow lipocalin multimerisation.

According to a further embodiment or aspect of the invention there is provided a lipocalin wherein said binding domain is adapted to bind more than one ligand and ideally said ligands are of a disparate nature according to the corresponding binding sites which are ideally based on different binding domains found in different lipocalins.

Methods for creating the above described lipocalins are well known in the art and comprise recombinant DNA techniques in the creation of lipocalin mutant and fusion proteins. It will also be apparent to those skilled in the art that the affinity of a lipocalin for a ligand can be altered, for example, by genetically modifying the ligand binding domain, to create an adapted lipocalin that has a higher affinity for a ligand. Moreover, the ligand binding domain may be genetically modified in this way to alter the specificity of ligand binding. It is also apparent that specificity of the targeting domain can be altered to either alter the specificity of targeting, or alternatively, increase or decrease the affinity of the targeting domain for its binding site. Genetic modification of this type is well known in the art and include, for example, the introduction of point mutations to alter the properties of the ligand binding site and/or the targetting

domain.

It is also apparent that the production of molecular complexes with more than one type of ligand binding domain can be produced. This can be achieved by the fusion of genes for the lipocalins to one another, with appropriate linking regions to produce a multi component gene and gene product. Or, interaction sites can be introduced into individual monomers of the lipocalins such that on mixing the individual proteins, molecules assemble into multi-sub unit complexes with similar or different functionalities. Genetic modifications of this type are well known in the art and include the introduction of point mutations, additions, deletion etc. to alter the properties of the protein. Additionally or alternatively, lipocalin monomers can be crosslinked to form multimeric complexes by chemical methods, including bifunctional cross-linking agents.

In yet a further preferred embodiment of the invention there is provided a lipocalin according to the invention wherein said lipocalin is manufactured using recombinant genetic techniques.

According to a further aspect of the invention there is provided a hair care composition comprising at least one lipocalin according to the invention.

In a preferred embodiment of the invention said composition comprises at least one lipocalin characterised in that it has the ability to bind fatty acids that coat hair cuticles or protein moieties that comprise the cuticle. More preferably still, said composition is further characterised in that it binds at least one ligand, the targetting of which to the hair has a beneficial effect.

In yet a further preferred embodiment said beneficial effect is a therapeutic or cosmetic effect.

It will be apparent to one skilled in the art that said cosmetic effect involves the targeting of said lipocalin to hair to provide a conditioning effect and moreover, as an alternative to or in combination with this, the targetting for example, of perfume or hair dye to hair to provide at least one desired effect.

It will be apparent to one skilled in the art that said therapeutic effect involves the targeting of said lipocalin to hair to prevent and/or cure a medical condition.

It will be apparent to one skilled in the art that an example of a lipocalin having a therapeutic effect is a lipocalin that binds and transports an insecticide to hair to prevent and/or cure infestation.

In a preferred embodiment of the invention said lipocalin composition is a veterinary composition for use in the treatment of parasitic infection of animals and/or birds.

In a further aspect of the invention there is provided a method for the treatment of humans and/or animals and/or birds which involves the administration of the therapeutic composition of the invention to an individual and/or animal and/or bird to prevent and/or cure a condition affecting hair, fur, hide, feathers or scalp.

It will be apparent that the lipocalin provides a biodegradable binding and/or targeting means to deliver agents to hair.

An embodiment of the invention will now be described, by example only, with reference to the following figures, methods and materials wherein;

Figure 1 represents a diagrammatic representation of conserved characteristics found in many lipocalins; and

Figure 2 represents a histogram showing the binding specificity of iodinated  $\beta$ -lactoglobulin for the hair cuticle.

## **Materials and Methods**

### **Radioiodination of $\beta$ -lactoglobulin**

$\beta$ -lactoglobulin was radiolabelled with Iodobeads ( Pierce ) and  $\text{Na}^{125}\text{I}$ , according to the manufacturers instructions.  $18\mu\text{g}$  ( $1\text{nmol}$ )  $\beta$ -lactoglobulin in  $18\mu\text{l}$  water was incubated for 5 minutes at room temperature with  $20\mu\text{l}$  ( $1\text{mCi}$ ) carrier free  $\text{Na}^{125}\text{I}$  in the presence of two washed Iodobeads in  $200\mu\text{l}$  of  $100\text{mM}$  sodium phosphate, pH 6.5. The reaction was terminated by removal of the Iodobeads with forceps. Ovalbumin, ( $0.2\%$  w/v) in  $100\text{mM}$  phosphate pH7.4,  $0.14\text{M}$  NaCl (PBS) was added to the reaction mixture to bring the volume up to  $0.5\text{ml}$ . Gel filtration was performed using Sephadex G-50 ( $30\times 0.9$ ) cm, equilibrated and developed with  $0.2\%$  (w/v) ovalbumin in PBS, immediately after the labelling reaction to remove excess  $\text{Na}^{125}\text{I}$ .

### **Assay for $^{125}\text{I}$ $\beta$ -Lactoglobulin Binding to Fatty Acids on the Surface of Hair**

The binding of [ $^{125}$ I] $\beta$ -lactoglobulin to cuticle cells was assayed in triplicate using an oil centrifuge method adapted from Sivaprasadorao (1987). 5mg of isolated hair were mixed with [ $^{125}$ I]-  $\beta$ -lactoglobulin in 100 $\mu$ l of assay buffer (20mM sodium phosphate, pH 7.4, 150mM NaCl). After incubation for 15 mins at 22°C, the mixture was centrifuged for 2mins at 12500xg followed by removal of the supernatant. A series of washes with centrifugation as above, were carried out to remove non-specifically bound [ $^{125}$ I]- $\beta$ -lactoglobulin:

**1<sup>st</sup> wash:** 2x 0.5ml 50mM Tris-Cl pH7.4, 0.5M NaCl ( high salt wash)

**2<sup>nd</sup> wash:** 2x0.5ml 50mM Tris-Cl pH7.4 ( low salt wash)

The cuticle sample was then overlaid with 300 $\mu$ l of dibutyl phthalate. Bound [ $^{125}$ I]  $\beta$ -lactoglobulin was separated from unbound material by centrifugation for 2 mins at 12500xg. The bottoms of tubes containing the cuticle pellet were cut off after freezing in a dry-ice bath, drained on a paper towel and then measured for radioactivity in a LKB Rack gamma counter. This gave total binding. Parallel incubations in the presence of a 10000-fold excess of unlabelled  $\beta$ -lactoglobulin were carried out to determine non-specific binding. Specific binding was calculated by subtracting the non-specific binding from total binding.

### **Methods for generation of lipocalin multimers**

There are a number of possible approaches to generating multimers of lipocalin molecules. Multimers generated can be homomeric or heteromeric and may comprise two lipocalin molecules (dimers) or higher order complexes (trimer and above). Preferred routes to generate heterodimers by chemical means are

outlined below.

### **Heterodimers cross-linked via the N-termini**

#### **Disuccinimidyl-suberimide-dihydrochloride (DSS).**

DSS is an homobifunctional reagent (*N*-hydroxysuccinimide ester) which reacts with primary amine groups in proteins linking them via their N-terminal amine or surface-exposed lysine amino groups. DSS was prepared as a fresh stock solution of 20mg/ml in ice-cold 25mM Na<sub>2</sub>HPO<sub>4</sub>/1mM-MgCl<sub>2</sub> (pH 8.0) and added to a 1mg/ml lipocalin preparation in the same buffer to give a working concentration of 0.5, 2.0 and 10mg/ml. The reactions were allowed to proceed at room temperature (21°C) for 1 hour and quenched by the addition of 50μl of 1.0M-ammonium acetate per ml of reaction mixture.

#### **Dimethyl-adipimide-dihydrochloride-(DMA)**

Conditions were identical to DSS treatment.

#### **1,5-difluoro-2,4-dinitrobenzene-(DFDNB)**

DFDNB was prepared as a 1.0M stock solution and added to the lipocalin suspension in 25mM Na<sub>2</sub>HPO<sub>4</sub> /1mM MgCl<sub>2</sub> (pH 8.0) to give a final concentration of 5.0mM. The reaction was terminated after 30 minutes at room temperature by dialysis against a large volume of 0.1M ammonium acetate (pH7.0).

***N*-hydroxysuccinimidyl 2,3-dibromopropionate (SDBP)**

SDBP is a heterobifunctional reagent (dibromopropionate and *N*-hydroxysuccinimide ester) used in sequential reactions to form the cross-link between the lipocalins. SDBP was prepared as a stock solution according to the manufacturer's instructions. The first lipocalin at a concentration of 1mg/ml was reacted with the *N*-hydroxysuccinimide moiety of SDBP added with constant stirring in phosphate buffer at pH 7 at 4°C for 1hr at an optimal concentration of SDBP. Excess cross-linker was removed by gel filtration and the derivatised lipocalin (now containing alkyldibromide groups on its surface) was reacted with the second lipocalin (total protein concentration of 1mg/ml) by elevation of the temperature to 21°C. This reaction was also carried out with constant stirring under the same buffer and pH conditions as for the first reaction.

**Heterodimers cross-linked via amino and carboxyl groups**

1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) is used to catalyse the formation of an amide bond between the N-terminal amino group (or side chain amino group of lysine) of one lipocalin and the C-terminal carboxyl group of a second lipocalin to form the desired heterodimer. EDC was prepared as a stock solution according to the manufacturer's instructions. Protein was suspended to a concentration of 1.0mg/ml in 2-[*N*-morpholino]-ethanesulphonic acid (MES) buffered saline at pH 4.5-5.0 and EDC added with stirring for 16 hr at 25°C at an optimal concentration of EDC.

**Heterodimers cross-linked via one amino group and one free cysteine**

residue.

Succinimidyl 4-[*N*-maleimidomethyl]-cyclohexane-1-carboxylate (SMCC) is a heterobifunctional cross-linking agent (*N*-hydroxysuccinimide ester and maleimide) that is used to sequentially react with the N-terminal amino group (or side chain amino group of lysine) of one lipocalin and a free sulphydryl group on the other. SMCC was prepared as a stock solution according to the manufacturer's instructions. The reaction with the *N*-hydroxysuccinimide moiety was carried out in phosphate buffer at pH7.0 with constant stirring at 4°C for 60min at an optimal concentration of SMCC. Excess cross-linker was removed by gel filtration and the derivatised lipocalin (now with attached maleimide moiety) reacted with a surface-exposed cysteine side chain on the second lipocalin. The maleimide reaction was performed in phosphate buffer at pH 6.5-7.5 with constant stirring at 4°C for 20 hr with a final protein concentration of 0.1-1.0mg/ml. This reaction is preferred where the first lipocalin lacks a free cysteine and the second lipocalin contains one.

Mixtures of undesirable lipocalin homodimers and the desired lipocalin heterodimers are isolated by a combination of two affinity chromatography steps that recognise the binding properties of both lipocalins. For most of the cross-linking agents outlined above analogues are available with different spacer arm lengths that could be used as necessary.

In general, for most of the cross-linking reactions outlined above the cross-linking reagents are used in 2-50 fold molar excess over protein; the actual concentration of cross-linker employed would also depend upon the protein concentration used. After completion of a cross-linking reaction excess or

hydrolysed cross-linker is quenched and removed by gel filtration, dialysis or centrifugal concentration according to well established practices in the art. The exact conditions of any particular cross-linking reaction, in terms of the reaction pH, temperature, time and concentration of protein and cross-linker, would need to be optimised for that particular reaction through experimentation.

## **Results**

A 1000-fold excess of unlabelled  $\beta$ -lactoglobulin competitively displaced approximately 20% of [ $^{125}\text{I}$ ] $\beta$ -lactoglobulin bound to the cuticle surface, see Table 1.

## **Conclusion**

It is concluded from these results that  $\beta$ -lactoglobulin binds specifically to the hair surface. The hydrophobic nature of the ligand binding site on the protein suggests that non-polar moieties on the cuticular surface may act as ligands for  $\beta$ -lactoglobulin. A prime example of this may be the cuticle. The rather non-selective nature of the  $\beta$ -lactoglobulin binding site opens up much scope for engineering into this protein much more effective interaction with the cuticle and hence hair fibre surface.

Table1

Total binding (A) $^{125}\text{I}$ $\beta$ -lactoglobulin	Non-specific binding (B) $^{125}\text{I}$ $\beta$ - lactoglobulin	Specific-binding (A-B)
10838cpm ( 0.005 $\mu\text{Ci}$ )*	8574cpm ( 0.004 $\mu\text{Ci}$ )	2264cpm ( 0.001 $\mu\text{Ci}$ )

\* Errors in these experiments are less than  $\pm 10\%$

PCT/GB00/0057

Harrison Goddard Foote

17/2/00

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**